Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
R Niehues, M Hasilik, G Alton, C Körner… - The Journal of …, 1998 - Am Soc Clin Investig
R Niehues, M Hasilik, G Alton, C Körner, M Schiebe-Sukumar, HG Koch, KP Zimmer, R Wu…
The Journal of clinical investigation, 1998•Am Soc Clin InvestigPhosphomannose isomerase (PMI) deficiency is the cause of a new type of carbohydrate-
deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1
gene. The clinical phenotype is characterized by protein-losing enteropathy, while
neurological manifestations prevailing in other types of CDGS are absent. Using standard
diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (
phosphomannomutase deficiency). Daily oral mannose administration is a successful …
deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1
gene. The clinical phenotype is characterized by protein-losing enteropathy, while
neurological manifestations prevailing in other types of CDGS are absent. Using standard
diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (
phosphomannomutase deficiency). Daily oral mannose administration is a successful …
Phosphomannose isomerase (PMI) deficiency is the cause of a new type of carbohydrate-deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1 gene. The clinical phenotype is characterized by protein-losing enteropathy, while neurological manifestations prevailing in other types of CDGS are absent. Using standard diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (phosphomannomutase deficiency). Daily oral mannose administration is a successful therapy for this new type of CDG syndrome classified as CDGS type Ib.
The Journal of Clinical Investigation